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Objective: We evaluated the efﬁcacy and safety of oral levosimendan in patients with a history of
cerebral ischemia.
Methods: In a randomized, double-blind, placebo-controlled, parallel-group study, 16 patients with
a history of ischemic stroke/transient ischemic attack received oral levosimendan in 5 escalating doses
from 0.125 to 2.0 mg daily for 18-day intervals of each dose; 5 patients received placebo. Twenty-four-
hour ambulatory ECG and cerebral blood ﬂow velocities using transcranial Doppler ultrasound were
recorded at baseline and at the end of each dosing period. Vasomotor reactivity was assessed via the
breath holding index. In addition, plasma levels of N-terminal-pro-B-type natriuretic peptide (NT-pro-
BNP) and the metabolites of levosimendan were determined.
Results: Levosimendan induced an increase in cerebral blood ﬂow velocities and a decrease in NT-pro-
BNP compared with placebo. There was no signiﬁcant effect on breath holding index. Doses Z0.5 mg
increased heart rate by 5 to 9 beats/min. The dose level of 2.0 mg exceeded the preset safety margin of
ventricular extrasystoles per hour (ie, upper 90% CI of the ratio of levosimendan to placebo above 2) with
an estimate of 3.10 (90% CI, 0.95–10.07).
Conclusions: Oral levosimendan increases cerebral blood ﬂow velocities and diminishes NT-pro-BNP
levels in patients with earlier ischemic cerebrovascular event. Daily doses up to 1.0 mg were well
tolerated, whereas the 2.0 mg dose level induced an increase in ventricular extrasystoles. ClinicalTrials.
gov identiﬁer: NCT00698763.
& 2015. The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Levosimendan is a calcium sensitizer with vasodilatory and
cardioprotective properties1 and is used as an intravenous treat-
ment for acute heart failure. It has been shown to exert beneﬁcial
hemodynamic and neurohormonal effects as well as reduce
symptoms in this patient population.2–5
Promising preclinical ﬁndings with levosimendan have recently
shifted the research interest into a new therapeutic area: PreventionInc. This is an open access article u
hD, Orion Pharma, Orionintie
M. Kivikko).of ischemic stroke. Orally administered levosimendan has been shown
to signiﬁcantly improve survival in preclinical models of primary and
secondary prevention of stroke. These studies also suggested a
beneﬁcial synergism in coadministration of levosimendanwith angio-
tensin II receptor blockers (ARBs).6 In a model of transient brain
ischemia by intraluminal occlusion of the middle cerebral artery in 40
male Wistar rats, intravenously administered levosimendan limited
the infarct size and brain swelling by 40% and 53%, respectively, but no
effect on neurologic outcome or mortality could be demonstrated.7
The putative mechanisms underlying the beneﬁcial effects of
levosimendan may be related to its vasodilatory and antiischemic
properties,1,8 improved endothelial function,9 and antiaggregatory
effect on platelets.10nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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limited to patients with heart failure. The largest study with oral
levosimendan, the PERSIST (effects of PERoral levoSImendan in the
prevention of further hoSpTalisations in patients with chronic
heart failure) study11 was a placebo-controlled study of 307
patients with severe chronic heart failure. Levosimendan doses
were 1 or 2 mg daily and the exposure was at least 180 days.
Levosimendan improved the quality of life, decreased N-terminal-
pro-B-type natriuretic peptide (NT-pro-BNP) levels, and improved
renal function, but resulted in an increase in heart rate (HR) of
about 8 beats/min. No signiﬁcant differences in the occurrence of
atrial or ventricular arrhythmias were seen.
We performed a pilot study for preliminary evaluation of
potential beneﬁts and safety of levosimendan in patients with an
earlier ischemic cerebrovascular event. Because the eventual
proarrhythmogenic effect of oral levosimendan is unsettled, we
included a thorough assessment of arrhythmias in our study. Our
primary objective was to explore the safety of oral levosimendan
and the primary safety variable was the number of ventricular
extrasystoles per hour (VES/h) in the 24-hour ambulatory ECG
monitoring. The secondary objective was to evaluate the potential
effect of levosimendan on cerebral circulation.Methods
The study was conducted in accordance with the ethical princi-
ples of the Declaration of Helsinki-Good Clinical Practice Guideline,
and the regulatory requirements. All patients provided written
informed consent before performance of any study procedure.
Design
This was a multicenter, Phase II, randomized, double-blind,
placebo-controlled, parallel-group study. The study was carried
out in 9 academic neurology centers in Finland, Germany, Hun-
gary, and Sweden. After randomization, all patients ﬁrst received
single-blind placebo for a maximum of 18 days (placebo run-in).
During the double-blind phase, 5 escalating doses of oral levosi-
mendan were given for a maximum of 18 days in 5 treatment
periods. The doses of levosimendan were 0.125, 0.25, 0.5, 1.0, and
2.0 mg once daily. Patients randomized to placebo received
placebo throughout all 5 periods.
Patients
Patients within the age range of 50 to 80 years with ischemic
stroke or transient ischemic attack (TIA) within 1 to 9 months before
the screening visit were included. Patients had to be receiving
maintenance treatment with an ARB or angiotensin-converting
enzyme inhibitor, cholesterol-lowering agent, and an antiaggregatory
agent, started at least 1 month before the screening visit.
The main exclusion criteria were stroke or TIA due to cardiac
embolism, vasculitis, or arterial dissection, a history of life-
threatening ventricular arrhythmias, or ventricular tachycardia in
the 24-hour ambulatory ECG at screening. Patients with severe
hemiparesis or dysphasia inhibiting the ability to fully comply
with the study protocol requirements were also excluded. In
practice, the exclusion and inclusion criteria restricted the patient
selection to a sample of stable patients with either a previous TIA
or a minor stroke of small-vessel and/or large-vessel etiology.
Assessments
Cerebral blood ﬂow velocities (peak, end diastolic, and mean) at
rest and after a 30-second breath holding were assessed atbaseline and at the end of each treatment period with transcranial
Doppler (TCD) ultrasonography.12 Each site used its own TCD
equipment, but a manual for performing the procedure was
created and presented at an investigators’ meeting before the
initiation of the study. The ﬂow velocities were measured via
transtemporal window, preferably from the side ipsilateral to the
ischemic event. However, if the affected side was clearly more
difﬁcult to visualize, then the contralateral side was used. If the
testing at screening visit could not be performed technically
reliably, the patient was to be excluded from the study. In
consecutive measurements during the study, the same side for
an individual patient was used. The blood ﬂow velocities were
measured from the M1 segment level of the middle cerebral
artery. Before each TCD examination, the patient rested for 5 to
10 minutes lying in a supine position with head straight. At the
end of the resting period, blood pressure and HR were recorded.
Cerebrovascular reactivity to hypercapnia was assessed by
means of breath holding index (BHI) using TCD ultrasonography.
Mean blood ﬂow velocity of the middle cerebral artery was
measured at rest (Vrest) and at the end of a breath holding period
of at least 30 seconds (VBH).
BHI was calculated using the following formula:
BHI¼ 100 ½ðVBH–VrestÞ=Vrest=T
where T is the period of breath holding in seconds, VBH is the
mean blood ﬂow velocity at the end of the breath holding period,
and Vrest is the mean blood ﬂow velocity at baseline during
normal breathing.
A 24-hour ambulatory 3-lead ECG (Holter) was recorded at
screening and at the end of each treatment period. The Holter
recordings were analyzed by a single central laboratory, which also
provided the recorders for the study centers. The central labora-
tory sent the analysis report to the study center, and the dose was
not increased until the report was available. The stopping rules for
dose escalation were a mean 24-hour HR increase of 415 beats/
min compared with screening and, at the same time, HR was to be
490 beats/min or the patient had to have symptoms related to
increased HR; ventricular tachycardia 410 consecutive beats;
symptomatic atrial ﬁbrillation requiring intervention; serious
adverse event; or the best interest of the patient as judged by
the investigator.
Plasma samples for the determination of NT-pro-BNP and the
levosimendan metabolites OR-1896 and OR-1855 were drawn at
baseline and at the end of each dosing period. The samples were
analyzed in central laboratories. A detailed description of the
analysis method for the metabolites has been published.13
Study Monitoring
The study was monitored by the sponsor (Orion Pharma, Espoo,
Finland). All study data were monitored and collected according to
the protocol (and amendments) and recorded on the sponsor’s
study-speciﬁc electronic case report forms using electronic data
capture. The study monitor veriﬁed that the case report forms
corresponded with source data. For this purpose, the study
monitor was allowed direct access to hospital or patient records
and original laboratory data as far as they were related to
the study.
Statistical Methods
The primary objective of our study was to explore the safety of
different doses of oral levosimendan in patients with an earlier
history of ischemic cerebrovascular event.
The number of VES/h in the 24-hour ambulatory ECG was the
primary safety variable in the study. The Holter recording of the
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changes. Number of VES/h, the cerebral blood ﬂow data from TCD
ultrasonography, vital signs, and NT-pro-BNP were summarized for
each dose level by randomization group, using descriptive statis-
tics. Repeated measures ANCOVA model with randomized treat-
ment and center as between factors, dose level as within factor,
and baseline value as covariate, were used to evaluate the differ-
ences between randomized treatment groups. Contrasts were used
to evaluate the safety of each dose level; that is, each levosimen-
dan dose was compared with placebo. In statistical analysis, log-
transformed VES/h data were used to ensure normality.
The primary safety objective was to show that there is at least
1 safe dose level of oral levosimendan compared with placebo.
A dose level doubling the prevalence of VES/h was considered
potentially proarrhythmic and unsafe (ie, levosimedan:placebo
42.00). Previous data suggest reasonable log-linear relationships
between the dose of levosimendan and the number of VES/h.14
Based on those assumptions, bootstrap simulation (5000 simula-
tions) was used to evaluate probabilities of a dosing group not
exceeding the safety margin (ie, levosimedan:placebo 42.00).
Evaluation of the safe dose was based on 2-sided 90% CIs; if the
upper limit of 90% CI lies above 2.00, it was to be concluded that the
dose is not safe. Simulations showed that 45 patients, randomized in
2:1 allocation, would provide 490% power to show that the median
dose (ie, 0.5 mg) is safe and to elicit a dose-dependent response.Results
Due to the slower-than-anticipated recruitment, the study was
prematurely discontinued. In total, 32 patients were screened, of
whom 11 were excluded for not meeting the eligibility criteria
(Figure 1). Thus, only 21 patients were included. Further, the
preplanned randomization ratio of 2:1 to levosimendan and
placebo turned out to be 3:1. Sixteen patients receivedNumber of subjects
screened
N = 32
Number of subjects
randomised
Levosimendan
N = 16
Number of subjects
randomised
Placebo
N = 5
Number of subjects
discontinued
 Period 6 N = 3
Number of subjects
completed
N = 13
Number of subjects
completed
N = 4
Number of subjects
discontinued
 Period 5 N = 1
Reasons for exclusion:
Inclusion/exclusion criteria
N = 11
Figure 1. Subject disposition. Period 5 refers to dose level 1 mg daily and period 6
to dose level 2 mg daily.levosimendan and 5 received placebo on top of their concomitant
medical treatment. Using the same log-linear relation as in the
original sample size calculations with 2-sided 90% CIs, it was
estimated that 20 study patients would still provide approximately
75% power to show that the median dose is safe.
Four out of the 21 patients (3 in the levosimendan group and
1 in the placebo group) did not receive all the dose levels. The
placebo patient discontinued because a stopping rule was met
(ventricular tachycardia of 410 consecutive beats), whereas
1 levosimendan patient discontinued due to the occurrence of
second-degree atrioventricular block, 1 levosimendan patient dis-
continued for adverse event (depression; best interest of a patient
as judged by the investigator) and 1 levosimendan patient dis-
continued for serious adverse event (sepsis, apnea, or epilepsy). All
discontinuations took place at the ﬁnal dose level (ie, 2.0 mg
daily). These discontinued patients were included in the intention-
to-treat analysis.
Baseline and demographic characteristics were comparable
between the treatment groups (Table I).
Cerebral Blood Flow
Levosimendan increased cerebral blood ﬂow velocities both
at rest and after breath holding without any apparent dose effect.
In Figure 2, the mean blood ﬂow velocities are shown for
individual dose levels both at rest and after breath holding. When
the results of all levosimendan dose levels were pooled and
compared with placebo, a statistically signiﬁcant difference (P o
0.001) from placebo was seen, both at rest and at the end of the
breath holding. At individual dose levels, the difference in the
change from baseline was signiﬁcant (P o 0.05) when compared
with placebo at rest with the lower levosimendan doses (0.125 and
0.25 mg); doses Z0.5 mg only achieved numerically increased
blood ﬂow velocities. At the end of the breath holding the pattern
was similar, with the signiﬁcant differences seen with the lower
doses only.
In BHI, there was no difference between placebo and the pooled
levosimendan dose levels - 0.77 [0.18] vs 0.76 [0.09]; P ¼ 0.977
(values expressed as mean [SEM]). Also, at individual dose levels,
no signiﬁcant differences to placebo were observed.
Arrhythmias
To assess the safe dose levels of levosimendan, the baseline-
adjusted number of VES/h at each dose level was compared with
the corresponding values in the placebo group (Figure 3).
Although the predeﬁned safety limit (upper 90% CI in levosimen-
dan:placebo 42) was marginally exceeded with the dose of
0.5 mg (but not with 0.125, 0.25, and 1.0 mg), only the highest
dose of 2.0 mg deﬁnitely exceeded the limit (levosimendan:
placebo estimate 3.10; lower 90% CI, 0.95; upper 90% CI, 10.07).
When inspecting the data from individual patients, it is evident
that the number of VES/h was fairly constant throughout the study
period in all patients in the placebo group. Of the 16 patients in the
levosimendan group, 10 (63%) had virtually no changes in the
number of VES/h throughout the study. On the other hand,
4 patients (25%) showed a consistent pattern with increases in
the number of VES/h at higher doses. At the 2 lowest doses (ie,
0.125 and 0.25 mg) none of the patients showed any appreciable
increase in the number of VES/h.
No episodes of sustained ventricular tachycardia were recorded.
Nonsustained ventricular tachycardia occurred in 5 levosimendan
patients (31%) and in 2 placebo patients (40%). Furthermore, only
1 patient taking levosimendan seemed to have a distinct pattern
with the occurrence of nonsustained ventricular tachycardia at all
doses from 0.25 mg and above. In the remaining patients, the
Table I
Summary of demographic and baseline characteristics.
Variable Levosimendan
(n ¼ 16)
Placebo
(n ¼ 5)
Male gender* 8 (50) 3 (60)
Age, y† 65 (9) 64 (9)
Previous cerebrovascular ischaemic event
(within 1–9 mo)*
Ischemic stroke 12 (75) 2 (40)
Transient ischaemic attack 4 (25) 3 (60)
Hypertension* 12 (75) 4 (80)
Diabetes mellitus* 4 (25) 1 (20)
Body mass index† 27 (3) 27 (5)
Systolic blood pressure, mm Hg† 138 (15) 143 (16)
Diastolic blood pressure, mm Hg† 79 (10) 86 (12)
Heart rate, beats/min† 72 (11) 78 (10)
Ventricular extrasystoles per hour† 4.8 (5) 6.6 (10)
Selected concomitant medications*
Angiotensin-converting enzyme inhibitors/
angiotensin II receptor blockers
16 (100) 5 (100)
Lipid-lowering agent 16 (100) 5 (100)
Aspirin alone or with dipyridamole 13 (81) 5 (100)
Dipyridamole alone or with aspirin 5 (31) 2 (40)
Clopidogrel 2 (13) 0 (0)
Transcranial Doppler variables†
At rest
Mean ﬂow velocity, cm/sec 48 (15) 48 (13)
End diastolic ﬂow velocity, cm/sec 35 (12) 37 (9)
Peak ﬂow velocity, cm/sec 75 (22) 72 (21)
After 30-sec breath holding
Mean ﬂow velocity, cm/sec 58 (22) 64 (19)
End diastolic ﬂow velocity, cm/sec 44 (19) 50 (14)
Peak ﬂow velocity, cm/sec 83 (31) 91 (31)
n Values are given as n (%).
† Values are given as mean (SD).
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maximum length of the nonsustained ventricular tachycardia was
10 beats in the levosimendan group and 16 beats in the
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Figure 2. Mean (SD) blood ﬂow velocities of the middle cerebral artery at different
dose levels. (*o0.05).No episodes of atrial ﬁbrillation or ﬂutter were observed in
either group. Supraventricular tachycardia occurred indiscrimin-
ately at some time point in the majority of patients in both
treatment groups.
HR and Blood Pressure
In the levosimendan group, the 24-hour mean HR was 72 beats/
min at baseline and remained constant with 0.125 and 0.25 mg
doses. Thereafter, the mean HR increased to 77, 78, and 80 beats/min
with 0.5, 1.0, and 2.0 mg doses, respectively. In the placebo group, the
mean HR varied between 69 and 80 beats/min at different time
points, without any deﬁnite trend. At doses of 0.5, 1.0, and 2.0 mg, the
difference between levosimendan and placebo groups was statisti-
cally signiﬁcant (P ¼ 0.017, P ¼ 0.023, and P o 0.0001, respectively).
There were no changes in systolic blood pressure with any of
the levosimendan doses. Diastolic blood pressure decreased stat-
istically signiﬁcantly only with the highest levosimendan dose (ie,
2.0 mg), by 6 mm Hg (P ¼ 0.022).
NT-Pro-BNP
The median NT-pro-BNP values at baseline were 129 ng/L and
127 ng/L in the levosimendan and placebo groups, respectively.
In the levosimendan group, the median NT-pro-BNP values
decreased from baseline during active treatment periods by 21%
to 58% (Figure 4). The decrease was statistically signiﬁcantly
different from placebo with doses 0.125, 1.0, and 2.0 mg (P ¼
0.039, P ¼ 0.021, and P ¼ 0.034, respectively).
Pharmacokinetic Properties
The plasma levels of levosimendan metabolites OR-1855 and
OR-1896 increased in a dose-dependent manner. Plasma concen-
trations at the end of each dosing level are shown in Figure 5.
There were no signiﬁcant correlations between the metabolite
levels and the mean cerebral blood ﬂow (data not shown).
Tolerability and Safety
The most common adverse event was ventricular tachycardia,
which was reported in 3 levosimendan-treated patients (19%) and
1 placebo patient (20%). Sinus tachycardia, chest discomfort,
gastroenteritis, back pain, and headache were reported in
2 patients receiving levosimendan each (13%). Sinus tachycardia
was reported by 1 patient (20%) and headache by 1 patient (20%)
in the placebo group.
Serious adverse events were reported in 2 patients receiving
levosimendan treatment: 1 had VES at the 2.0 mg dose level and
the other had sepsis, epilepsy, and apnea also at the 2.0 mg dose0
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Figure 3. Statistical model based estimates (and 90% CI) for the levosimendan/
placebo ratio of the number of VES/h.
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Figure 4. Median NT-pro-BNP values during the study.
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Figure 5. Mean (SD) plasma concentrations of levosimendan metabolites OR-1855
and OR-1896 at the end of each dosing period.Discussion
Low oral levosimendan doses induced an increase in cerebral
blood ﬂow velocities in our study. The cerebral blood ﬂow was
assessed using transcranial Doppler method, which is a surrogate
for cerebral blood ﬂow. Bravo et al15 showed improved cerebral
perfusion and oxygenation with intravenous levosimendan in
critically ill infants. Because levosimendan is a vasodilating agent
that does not cause vasospasm in any arterial bed,16 the likely
explanation is a vasodilatory effect in the brain circulation. It is of
importance that the effect was evident despite the fact that all
patients were receiving an effective vasodilatory treatment with
either ARB or angiotensin-converting enzyme inhibitor. Because
there was no effect on the BHI, levosimendan did not seem to
interfere with the carbon dioxide reactivity of cerebral arteries.
The BHI levels were consistently fairly low in this population,
which may be a confounding factor (ie, associated with greater
arterial stiffness).
The antiaggregatory effects of levosimendan on platelets could
also be of importance in stroke prevention. Although we did not
study this, earlier data indicate that levosimendan has antiaggre-
gatory effects.10 Cilostazol has shown beneﬁcial effect on secon-
dary stroke prevention in clinics.17 Its main mechanism of action is
believed to be its antiaggregatory effects, but as a phosphodiester-
ase inhibitor, it also has vasodilatory effects.17 Therefore, multiple
mechanisms of both levosimendan and cilostazol could potentially
underlie their eventual efﬁcacy in stroke prevention.
Assessing the proarrhythmic potential of levosimendan was in
a crucial role in our study. The occurrence of ventricular tachy-
cardia has been shown to be a clinically relevant predictor of
proarrhythmia.18 However, its expected incidence was considered
low in our small-scale study of patients without evident heart
disease. We therefore decided to use the number of VES/h as a
surrogate marker for proarrhythmia.
Earlier data indicate that a high frequency of VES/h is correlated
with a worse prognosis. Mortality is higher in patients with
myocardial infarction with a number of VES/h exceeding 30
compared with those with o30 VES/h.19 Furthermore, the occur-
rence of VES in a 2-minute ECG recording has been shown to be an
independent risk factor for stroke in a large, community-based
cohort of about 15,000 middle-aged subjects and a follow-up of up
to 17 years. The hazard ratio for stroke was 1.7 in those with at
least 1 VES in a 2-minute ECG (corresponding with Z30 VES/h).20
There is no commonly accepted rule for a clinically relevant
increase in VES/h to herald an increased risk of severeproarrhythmic events. Further, the signiﬁcance of the increase of
VES as a predictor of proarrhythmic potential of a medication is
even more limited. We hypothesized that a 2-fold increase in the
number of VES/h could be of clinical importance. Only the highest
dose—2.0 mg levosimendan daily—crossed this arbitrary line for
proarrhythmia in our study.
Possible treatment effects on HR are also relevant for long-term
safety, because elevated HR may increase myocardial oxygen
consumption and thus be deleterious in ischemic conditions.
Levosimendan did not inﬂuence the mean 24-hour HR at the
0.125- and 0.25-mg doses, whereas an increase of 5 to 9 beats/min
was observed with the higher doses. For comparison, in the
PERSIST study,11 1.0- and 2.0-mg doses of levosimendan resulted
in an increase in HR of about 8 beats/min, which is similar to that
observed in our study. The mechanism underlying the increase in
HR is not known, but a direct increasing effect on sinus nodal rate
has been suggested.21
In accordance with data in patients with heart failure,11
levosimendan signiﬁcantly decreased NT-pro-BNP in our study.
The effect is probably related to vasodilation and decreased left
ventricular ﬁlling pressure.22 These effects, which are favorable in
patients with heart failure, would possibly also be favorable in our
study population. Patients with a history of previous stroke have
a higher incidence of left ventricular dysfunction than matched
controls.23
The pharmacokinetic properties of levosimendan induce cer-
tain limitations to constant oral dosing. Levosimendan has an
elimination half-life of about 1 hour, but its metabolites, OR-1855
and OR-1896, have a half-life of about 70 to 80 hours in patients
with heart failure.24 The daily oral levosimendan dose must
remain relatively low to avoid excessive accumulation of the
metabolites. The metabolite OR-1896 has similar pharmacologic
effects to the parent drug,1 and in long-term oral treatment the
clinical effects are mostly related to the active metabolite instead
of levosimendan itself.11 The 18-day dosing for each dose level in
our study was selected to ensure that a steady-state level for the
metabolites was reached by the end of the dosing period.
The plasma levels of the levosimendan metabolites OR-1855
and OR-1896 in our study were approximately half of those seen in
patients with heart failure who were given oral levosimendan for
2 weeks.13 The elimination half-life of the metabolites is consid-
erably lower in healthy volunteers25 than in patients with heart
failure;24 that is, 44 to 61 hours versus 70 to 80 hours, respectively.
Although not measured in our study, the lower steady state of the
metabolites suggests that the elimination half-life in a noncardiac
stroke population is closer to that seen in healthy volunteers.
A major limitation of the study is the small number of patients
included. Another limitation is the noncentralized reading of TCD
imaging, although measures to harmonize the technical perform-
ance were taken.
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We showed that low oral levosimendan doses increase cerebral
blood ﬂow velocities and decrease NT-pro-BNP in patients with an
earlier ischemic cerebrovascular event. Increased cerebral blood
ﬂow velocities were seen when levosimendan was administered as
an add-on therapy to other drugs commonly used in secondary
prevention of stroke. In preclinical models, levosimendan has
shown beneﬁcial outcome effects. However, it remains unknown
whether the improved cerebral blood ﬂow velocities induced by
levosimendan have any clinical implications in the secondary
prevention of stroke. On the whole, the preliminary safety proﬁle
was acceptable in this population; only the highest dose—2.0 mg
daily—increased the number of VES/h compared with placebo. No
episodes of atrial ﬁbrillation or ﬂutter were observed.Acknowledgments
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